Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

Therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Bora Pharmaceuticals also offers lyophilization, terminal sterilization, analytical, stability, and packaging and serialization services.